All In MedTech

FDA Clearance Tracker · P860004-S275

SynchroMed Infusion System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 21, 2017

Approved

Time to decision

238 days

Received Apr 27, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P860004-S275
Device name
SynchroMed Infusion System
Applicant location
Minneapolis, MN
Received
Apr 27, 2017
Decided
Dec 21, 2017
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P860004

Device type

Device class
Class III

Every decision under product code LKK

FDA's approval statement

As written in FDA's record.

Approval for changes made to the design history file and device master record of the motor component of the SynchroMed II Programmable Drug Infusion Pump (Model 8637), the associated parts of the motor (i.e. assemblies, subassemblies, components, subcomponents, and materials used in the manufacturing of the motor assembly), and the pumphead assembly material specifications.

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.